# Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)

> **NCT07435584** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 38 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Everolimus (Afinitor) tablets

## Key facts

- **NCT ID:** NCT07435584
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07435584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07435584, "Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07435584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*